Skip to main content
. 2014 Jul 28;12(8):4291–4310. doi: 10.3390/md12084291

Figure 6.

Figure 6

(A) Representative immunohistochemical staining for p-Akt, p-Bad and caspase-3 in the cortex of the SAH + ATX and SAH + ATX + LY294002 groups. As shown, there was a strong immunoactivity of p-Akt and p-Bad and slight immunoactivity of caspase-3 in the cortex of the SAH + ATX group. However, after administration of LY294002, the immunoactivity of p-Akt and p-Bad significantly decreased compared with that in the SAH + ATX group. Moreover, LY294002 administration could upregulate the caspase-3 level when compared with that in the SAH + ATX group. These results suggested that the PI3K inhibitor LY294002 treatment could partially abolish the protective effects of ATX in the EBI after SAH; (B) Quantitative analysis of the p-Akt, p-Bad and caspase-3 immunohistochemical staining in the cerebral cortex in the SAH + ATX and SAH + ATX + LY294002 groups. Values are expressed as the mean ± SEM. ** p < 0.01, * p < 0.05, ns p > 0.05.